Loading...
XMAD
ECR
Market cap284mUSD
Apr 09, Last price  
2.77EUR
1D
0.00%
1Q
-21.75%
Jan 2017
50.54%
Name

Ercros SA

Chart & Performance

D1W1MN
P/E
P/S
0.38
EPS
Div Yield, %
3.47%
Shrs. gr., 5y
-3.32%
Rev. gr., 5y
-0.07%
Revenues
667m
-7.98%
432,800,000774,410,000870,090,000866,490,000612,540,000609,280,000686,040,000677,530,000624,970,000603,670,000618,270,000602,540,000685,970,000671,940,000669,782,000568,797,000800,055,000998,532,000725,294,000667,415,000
Net income
-12m
L
38,500,0004,850,000-33,510,000-20,302,000,000-49,820,000-12,470,000-900,000-12,130,000-3,750,000-6,290,0007,240,00045,160,00044,582,00044,876,00031,043,0006,257,00043,297,00062,989,00027,585,000-11,657,000
CFO
0k
-100.00%
-650,000-14,540,00031,620,000-680,000,00040,910,000-10,580,00011,520,00019,170,00023,860,00028,050,00014,000,00038,950,00043,813,00044,876,00059,431,00074,591,00060,324,00062,989,00051,140,0000
Dividend
Jul 08, 20240.096 EUR/sh
Earnings
Apr 28, 2025

Profile

Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing chipboards, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; plugs and switches in the electrical components sector; and household, sanitary, and packaging materials in the textile tanning industry. The Pharmacy division engages in the production of raw materials and intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, calcium and sodium fosfomycin, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.
IPO date
Sep 17, 1990
Employees
1,343
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
667,415
-7.98%
725,294
-27.36%
998,532
24.81%
Cost of revenue
453,254
529,712
756,913
Unusual Expense (Income)
NOPBT
214,161
195,582
241,619
NOPBT Margin
32.09%
26.97%
24.20%
Operating Taxes
(597)
(23,764)
17,314
Tax Rate
7.17%
NOPAT
214,758
219,346
224,305
Net income
(11,657)
-142.26%
27,585
-56.21%
62,989
45.48%
Dividends
(8,778)
(13,715)
(8,211)
Dividend yield
2.77%
5.55%
2.69%
Proceeds from repurchase of equity
(11,134)
(14,380)
BB yield
4.51%
4.71%
Debt
Debt current
81,211
31,732
30,945
Long-term debt
105,105
108,777
116,806
Deferred revenue
11,874
13,334
12,802
Other long-term liabilities
18,574
19,686
23,080
Net debt
154,824
42,845
53,515
Cash flow
Cash from operating activities
51,140
62,989
CAPEX
(13,558)
(14,194)
(27,184)
Cash from investing activities
(26,666)
(33,835)
(52,814)
Cash from financing activities
14,329
(35,911)
(21,455)
FCF
172,074
229,759
191,883
Balance
Cash
31,492
39,145
55,480
Long term investments
58,519
38,756
Excess cash
61,399
44,309
Stockholders' equity
15,774
363,115
431,335
Invested Capital
543,940
465,985
483,364
ROIC
42.53%
46.21%
47.19%
ROCE
37.78%
35.49%
43.88%
EV
Common stock shares outstanding
89,669
93,587
94,229
Price
3.53
33.71%
2.64
-18.52%
3.24
9.09%
Market cap
316,532
28.11%
247,070
-19.07%
305,303
4.06%
EV
471,356
289,915
358,818
EBITDA
214,161
195,582
271,585
EV/EBITDA
2.20
1.48
1.32
Interest
6,708
9,793
3,787
Interest/NOPBT
3.13%
5.01%
1.57%